[ad_1] SUMMARY Stocks to watch, NTPC, Bajaj Auto, GR Infraprojects, Brigade Enterprises, Hindustan Zinc, Zydus Lifesciences and more, these are the stocks to watch for tomorrow. 1 / 6 NTPC | State-owned power giant announced plans to issue unsecured, non-convertible debentures (NCDs) worth ₹4,000 crore on March 20, 2025, through a private placement. The NCDs […]
Zydus Lifesciences gets final FDA approval for prostate cancer drug – CNBC TV18
[ad_1] Drug maker Zydus Lifesciences Ltd on Tuesday (March 18) said it has received the final approval from the United States Food and Drug Administration (FDA) to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 mg. Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with […]
Zydus Life receives final approval from USFDA for Eluxadoline Tablets – CNBC TV18
[ad_1] Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to manufacture Eluxadoline Tablets, 75 mg and 100 mg. Eluxadoline is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhoea. Eluxadoline tablets will be produced at Zydus Lifesciences Ltd (SEZ) in Ahmedabad, the […]
Stocks to Watch on March 17: IndusInd Bank, Infosys, Wipro, Brigade Enterprises and more – CNBC TV18
[ad_1] 1 / 17 IndusInd Bank | The Reserve Bank of India (RBI) issued a statement addressing speculation regarding IndusInd Bank Ltd, stating that the bank remains well-capitalised and financially stable. According to the RBI, IndusInd Bank reported a Capital Adequacy Ratio of 16.46% and a Provision Coverage Ratio of 70.20% for the quarter that […]
Zydus Lifesciences’ API unit in Ankleshwar, Gujarat clears USFDA inspection with nil observations – CNBC TV18
[ad_1] Drug maker Zydus Lifesciences Ltd on Friday (March 14) announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its API Unit 1 in Ankleshwar, Gujarat. The surveillance inspection, conducted from March 10 to March 14, 2025, concluded without any observations. “We wish to inform that the USFDA conducted […]
Zydus Lifesciences’ venture arm invests in Illexcor Therapeutics for sickle cell disease therapies – CNBC TV18
[ad_1] Zydus Lifesciences Ltd on Wednesday (March 12) said the company’s venture capital arm Zynext Ventures USA LLC has announced an investment in Illexcor Therapeutics, a biopharmaceutical company focused on developing next-generation oral therapies for sickle cell disease (SCD). The investment aligns with Zynext Ventures’ strategy of supporting breakthrough healthcare innovations that address significant unmet […]
Zydus Lifesciences gets final USFDA approval to manufacture antifungal shampoo – CNBC TV18
[ad_1] Zydus Lifesciences Ltd announced on Monday that it has received a final approval from the United States Food and Drug Administration (USFDA) for Ketoconazole Shampoo, an antifungal medication. The pharmaceutical company has been awarded the final approval by the US drug regulator for manufacturing Ketoconazole Shampoo, 2%. The USFDA approval for the production of […]
Zydus Lifesciences secures US FDA approval for generic Dasatinib tablets in the US – CNBC TV18
[ad_1] Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug Administration (USFDA) to market Dasatinib tablets in multiple strengths —20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. “Zydus has received final approval from the United States Food and Drug […]
Stocks to Watch on February 17: BHEL, Samvardhana Motherson, RVNL, Glenmark Pharma and more – CNBC TV18
[ad_1] 1 / 14 BHEL | State-run engineering giant announced a significant contract win, securing an order worth ₹6,700 crore from Singareni Collieries Company (SCCL) to establish an 800 MW thermal power unit in Telangana. The contract, awarded on an Engineering, Procurement, and Construction (EPC) basis, covers the design, engineering, manufacturing, supply, erection, commissioning, and […]
Zydus Lifesciences’ Maharashtra API unit clears US FDA inspection with no observations – CNBC TV18
[ad_1] Zydus Lifesciences Ltd on Friday (February 14) announced the successful completion of a US Food and Drug Administration (FDA) surveillance inspection at its API (active pharmaceutical ingredient) manufacturing facility in Ambernath, Maharashtra. Company Value Change %Change The inspection, conducted from February 10 to 14, 2025, concluded with no observations. “We wish to inform that […]